LB Pharmaceuticals Inc. (LBRX)

LB Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Selling, General & Admin	-	13.66	3.53
Research & Development	-	51.17	7.85
Operating Expenses	-	64.83	11.38
Operating Income	-32.91	-64.83	-11.38
Interest Expense / Income	-1.1	-1.72	4.01
Other Expense / Income	-2.39	-0.01	-9.12
Pretax Income	-29.43	-63.1	-6.27
Income Tax	0	0	0
Net Income	-29.43	-63.1	-6.28
Free Cash Flow	-42.13	-53.82	-12.12
EBITDA	-30.52	-64.77	2.06
Depreciation & Amortization	0	0.06	4.32
EBIT	-30.52	-64.82	-2.26

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).